ClinicalTrials.gg
WithdrawnNCT01697514Updated Aug 27, 2013

A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma

A Phase 1 interventional study of LY2940680 and LY2940680 in Medulloblastoma, Childhood and Rhabdomyosarcoma, sponsored by Eli Lilly and Company. Withdrawn at 4 sites in United States. Open to participants aged 12 Months to 21 Years. Per ClinicalTrials.gov, last updated 2013-08-27.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Trial stopped early for poor accrual.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
12 Months to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 245 studies in Medulloblastoma with a site in United States — 26 open to participants now, 53 under way, 2 of them phase 3. Medulloblastoma · United States.

Enrollment
212th of 215
0 · median 30
Started
2013
with 10 others
Phase 1
115 of 245
10 open now
Registered
134th of 245
by date

Among the 245 studies in Medulloblastoma with a site in United States, this one is the 212th largest by enrollment of the 215 interventional ones that give a count, is one of 11 that started in 2013, is one of 115 in phase 1, and was the 134th registered.

Medulloblastoma

317 studies on the registry are indexed under Medulloblastoma; 52 are open to participants now.

Browse Medulloblastoma studies →

Open to participants now

26 of the 245 studies in Medulloblastoma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 32 (84%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 12 Months to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Medulloblastoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to find a recommended dose level of LY2940680 that can be safely given to children with medulloblastoma or rhabdomyosarcoma that has returned or doesn't respond to initial treatment. The study will also explore the changes in a cancer marker levels. Finally, the study will help document any antitumor activity.

03

Conditions studied

  • Medulloblastoma, Childhood
  • Rhabdomyosarcoma

Keywords

  • recurrent medulloblastoma
04

Who can participate

Ages eligible
12 Months to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Part A: Have a diagnosis of recurrent or rhabdomyosarcoma or medulloblastoma and have had histologic verification of at original diagnosis or relapse.
  • For Part B: Have a diagnosis of recurrent or refractory medulloblastoma and have had histologic verification of malignancy at original diagnosis or relapse.
  • Current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.
  • score must be at least 50% for participants >16 years of age, and Lansky score must be at least 50% for participants 16 years of age or less. Participants who are unable to walk because of paralysis, but who are in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • Have fully recovered from the acute toxic effects of all prior anticancer chemotherapy.

    • Participants with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment in this study (6 weeks, if previously treated with nitrosourea).
    • Hematopoietic growth factors: At least 14 days after the last dose of a longacting growth factor (eg, Neulasta®) or 7 days for short-acting growth factor.
    • Biologic (antineoplastic agent): At least 7 days after the last dose of a biologic agent.
    • Immunotherapy: At least 6 weeks since the completion of any type of immunotherapy (eg, tumor vaccines).
    • Monoclonal antibodies: At least 3 half-lives of the antibody after the last dose of a monoclonal antibody.
    • Radiation therapy (XRT): ≥8 weeks for local irradiation to primary tumor;≥2 weeks prior to study entry for focal irradiation for symptomatic sites; ≥3 months for craniospinal XRT, or ≥24 weeks if ≥50% radiation of pelvis; minimum of 6 weeks must have elapsed if other substantial bone marrow radiation has been received.
    • Stem cell transplant: allowed if they have recovered from all acute toxicity and adequate bone marrow reserve is demonstrated. At least 8 weeks must have elapsed since stem cell transplantation or ≥3 months for allogenic transplantation. Participants must be off all therapy and have no evidence of active .
  • Have adequate organ function, including:

    • Bone marrow: Peripheral (ANC) ≥500/cubic millimeter (mm\^3) and count ≥100,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment).
    • Hepatic: (sum of conjugated + unconjugated)≤1.5 × (ULN) for age. Serum (ALT) and aspartate aminotransferase (AST) ≤2.0 times ULN for age. Serum albumin ≥2 grams/deciliter (g/dL).
    • Renal: or radioisotope (GFR)

      ≥70 milliliters/minute/1.73 square meters (mL/min/1.73 m\^2), or a serum creatinine based on age/gender per the Schwartz formula for estimating GFR utilizing child length and stature data published by the Centers for Disease Control and Prevention (CDC).

    • Neurologic: Participants with seizure disorders may be enrolled if receiving nonenzyme-inducing anticonvulsants and if the symptoms are well controlled. They must have a stable neurologic status for at least 1 week prior to enrollment in the study.
  • Must be able to swallow powder or a capsule.
  • Have the presence of either measurable or nonmeasurable disease.

Exclusion criteria

Exclusion Criteria:

  • Have received treatment within 21 days of the initial dose of study drug with an experimental agent for noncancer indications that has not received regulatory approval for any indication.
  • Receiving and have not been on a stable or decreasing dose of corticosteroid for the prior 7 days.
  • Receiving enzyme-inducing anticonvulsants.
  • Have serious preexisting medical conditions.
  • Have current hematologic or acute or chronic leukemia.
  • Have a known active fungal, bacterial, and/or known viral infection, including (HIV) or viral (A, B, or C) hepatitis (screening is not required).
  • Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
  • Have ≥Grade 2 , that is, QTc interval of >480 milliseconds (msec) on screening electrocardiography ().
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part A: LY2940680 (Dose Escalation)

    LY2940680 administered orally once daily at escalating doses (92.5 milligrams per square meter \[mg/m\^2\] up to 370 mg/m\^2) for two 28 day cycles. Lower dose levels (23 mg/m\^2 and 46 mg/m\^2) may also be explored, if necessary. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.

    Drug: LY2940680

  • Experimental
    Part B: LY2940680 (Dose Confirmation)

    LY2940680 administered orally once daily for two 28 day cycles. Dose based on Part A. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.

    Drug: LY2940680

Interventions

  • Capsule administered orally.

  • Powder administered orally (may be sprinkled on soft food).

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose of LY2940680

    Time frame: Baseline to Part A Completion (estimated as 12 months)

Secondary outcomes

  1. Pharmacokinetics: Area Under the Concentration - Time Curve (AUC) of LY2940680 and LSN2941091

    Time frame: Predose up to 24 hours Postdose

  2. Pharmacokinetics: Maximum Concentration (Cmax) of LY2940680 and LSN2941091

    Time frame: Predose up to 24 hours Postdose

  3. Pharmacokinetics: Time of Maximal Concentration (Tmax) of LY2940680 and LSN2941091

    Time frame: Predose up to 24 hours Postdose

  4. Number of Participants with Tumor Response

    Time frame: Baseline to Study Completion (estimated as 44 months)

07

Study locations

4 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Diego, California 92123, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aurora, Colorado 80045, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cincinnati, Ohio 45229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Portland, Oregon 97239, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2012
First posted
Oct 2, 2012
Start
Jul 2013
Primary completionEst.
Jul 2016
CompletionEst.
Jul 2016
Last update
Aug 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01697514
Responsible party
Sponsor
First posted
Oct 2, 2012
Start date
Jul 2013
Primary completion
Jul 2016 (estimated)
Completion
Jul 2016 (estimated)
Last update
Aug 27, 2013

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY2940680

Start the discussion